## SEQUENCE LISTING

```
<110> Boehringer Ingelheim Pharma KG
  <120> Method for identifying substances which positively
        influence inflammatory conditions
  <130> 1/1179
  <140>
  <141>
  <150> US 60/257,856
  <151> 2000-12-22
  <160> 8
<170> PatentIn Ver. 2.1
<210> 1
  <211> 63
(212> DNA
<213> Artificial Sequence
4 <220>
[] <223> Description of Artificial Sequence: Primer
ggccagtgaa ttgtaatacg actcactata gggaggcggt ttttttttt tttttttt 60
ļ.,.j.,
(210> 2
<sup>‡</sup>- <211> 25
  <212> DNA
  <213> Artificial Sequence
  <223> Description of Artificial Sequence: Primer
  <400> 2
  gtcgtcaaga tgctaccgtt cagga
                                                                      25
  <210> 3
  <211> 802
  <212> DNA
  <213> Homo sapiens
  <400> 3
  ggagggccgg gcaccgcggc atggagggtc aacgctggct gccgctggag gccaatcccg 60
  aggtcaccaa ccagtttctt aaacaattag gtctacatcc taactggcaa ttcgttgatg 120
  tatatggaat ggatcctgaa ctccttagca tggtaccaag accagtctgt gcagtcttac 180
  ttctctttcc tattacagaa aagtatgaag tattcagaac agaagaggaa gaaaaaataa 240
  aatctcaggg acaagatgtt acatcatcag tatatttcat gaagcaaaca atcagcaatg 300
  cctgtggaac aattggactg attcatgcta ttgcaaacaa taaagacaag atgcactttq 360
  aatctggatc aaccttgaaa aaattcctgg aggaatctgt gtcaatgagc cctgaagaac 420
```

gagccagata cctggagaac tatgatgcca tccgagttac tcatgagacc agtgccatg 480 aaggtcagac tgaggcacca agtatagatg agaaagtaga tcttcatttt attgcattag 540 ttcatgtaga tgggcatctc tatgaattag atgggcggaa gccatttcca attaaccatg 600 gtgaaactag tgatgaaact ttattagagg atgccataga agtttgcaag aagtttatgg 660 agcgcgaccc tgatgaacta agatttaatg cgattgctct ttctgcagca tagcttgtca 720 ataatggaaa caccaaaaac tgtattattt gcaactaaat tttctctgcc catacactaa 780 ctcaaaaatt ttgatattt cc

<210> 4

<211> 230

<212> PRT

<213> Homo sapiens

<400> 4

Met Glu Gly Gln Arg Trp Leu Pro Leu Glu Ala Asn Pro Glu Val Thr
1 5 10 15

Asn Gln Phe Leu Lys Gln Leu Gly Leu His Pro Asn Trp Gln Phe Val 20 25 30

Asp Val Tyr Gly Met Asp Pro Glu Leu Leu Ser Met Val Pro Arg Pro 35 40 45

Val Cys Ala Val Leu Leu Phe Pro Ile Thr Glu Lys Tyr Glu Val
50 60

Phe Arg Thr Glu Glu Glu Lys Ile Lys Ser Gln Gly Gln Asp Val 65 70 75 80

Thr Ser Ser Val Tyr Phe Met Lys Gln Thr Ile Ser Asn Ala Cys Gly
85 90 95

Thr Ile Gly Leu Ile His Ala Ile Ala Asn Asn Lys Asp Lys Met His 100 \$105\$ 110

Phe Glu Ser Gly Ser Thr Leu Lys Lys Phe Leu Glu Glu Ser Val Ser 115 120 125

Met Ser Pro Glu Glu Arg Ala Arg Tyr Leu Glu Asn Tyr Asp Ala Ile 130 135 140

Arg Val Thr His Glu Thr Ser Ala His Glu Gly Gln Thr Glu Ala Pro 145 150 155 160

Ser Ile Asp Glu Lys Val Asp Leu His Phe Ile Ala Leu Val His Val 165 170 175

Asp Gly His Leu Tyr Glu Leu Asp Gly Arg Lys Pro Phe Pro Ile Asn 180 185 190

His Gly Glu Thr Ser Asp Glu Thr Leu Leu Glu Asp Ala Ile Glu Val 195 200 205

Cys Lys Lys Phe Met Glu Arg Asp Pro Asp Glu Leu Arg Phe Asn Ala 210 215 220



```
Ile Ala Leu Ser Ala Ala
                      230
   225
   <210> 5
   <211> 50
   <212> DNA
   <213> Artificial Sequence
   <223> Description of Artificial Sequence: Primer
   <400> 5
   ggggacaagt ttgtacaaaa aagcaggcta tggagggtca acgctggctg
                                                                    50
   <210> 6
   <211> 50
   <212> DNA
   <213> Artificial Sequence
fU
ĘŪ
   <223> Description of Artificial Sequence: Primer
M
U
   <400> 6
   ggggaccact ttgtacaaga aagctgggtc tatgctgcag aaagagcaat
                                                                    50
æ
<u>}</u>=
   <210> 7
TU
   <211> 866
   <212> DNA
1
   <213> Homo sapiens
14
   <400> 7
   atggcggagc gcgggtacag cttttcgctg actacattca gcccgtctgg taaacttgtc 60
   cagattgaat atgctttggc tgctgtagct ggaggagccc cgtccgtggg aattaaagct 120
   gcaaatggtg tggtattagc aactgagaaa aaacagaaat ccattctgta tgatgagcga 180
   agtgtacaca aagtagaacc aattaccaag catataggtt tggtgtacag tggcatgggc 240
   cccgattaca gagtgcttgt gcacagagct cgaaaactag ctcaacaata ctatcttgtg 300
   taccaagaac ccattcctac agctcagctg gtacagagag tagcttctgt gatgcaagaa 360
   tatactcagt caggtggtgt tcgtccattt ggagtttctt tacttatttg tggttggaat 420
   gagggacgac catatttatt tcagtcagat ccatctggag cttactttgc ctggaaagct 480
   acagcaatgg gaaagaacta tgtgaatggg aagactttcc ttgagaaaag atataatgaa 540
   gatctggaac ttgaagatgc cattcataca gccatcttaa ccctaaagga aagctttgaa 600
   gggcaaatga cagaggataa catagaagtt ggaatctgca atgaagctgg atttaggagg 660
   cttactccaa ctgaagttaa ggattacttg gctgccatag cataacaatg aagtgactga 720
   cagacttttt gcatacttat ttctacatgg tttaaatcga ctgtttttaa aatgacactt 840
                                                                    866
   ataaatccta ataaactgtt aaaccc
   <210> 8
    <211> 234
    <212> PRT
    <213> Homo sapiens
    <400> 8
```

Met Ala Glu Arg Gly Tyr Ser Phe Ser Leu Thr Thr Phe Ser Pro Ser 1 5 10 15

Gly Lys Leu Val Gln Ile Glu Tyr Ala Leu Ala Ala Val Ala Gly Gly
20 25 30

Ala Pro Ser Val Gly Ile Lys Ala Ala Asn Gly Val Val Leu Ala Thr 35 40 45

Glu Lys Lys Gln Lys Ser Ile Leu Tyr Asp Glu Arg Ser Val His Lys
50 60

Val Glu Pro Ile Thr Lys His Ile Gly Leu Val Tyr Ser Gly Met Gly 65 70 75 80

Pro Asp Tyr Arg Val Leu Val His Arg Ala Arg Lys Leu Ala Gln Gln 85 90 95

Tyr Tyr Leu Val Tyr Gln Glu Pro Ile Pro Thr Ala Gln Leu Val Gln 100 105 110

Arg Val Ala Ser Val Met Gln Glu Tyr Thr Gln Ser Gly Gly Val Arg 115 120 125

Pro Phe Gly Val Ser Leu Leu Ile Cys Gly Trp Asn Glu Gly Arg Pro 130 135 140

Tyr Leu Phe Gln Ser Asp Pro Ser Gly Ala Tyr Phe Ala Trp Lys Ala 145 150 155 160

Thr Ala Met Gly Lys Asn Tyr Val Asn Gly Lys Thr Phe Leu Glu Lys
165 170 175

Arg Tyr Asn Glu Asp Leu Glu Leu Glu Asp Ala Ile His Thr Ala Ile 180 185 190

Leu Thr Leu Lys Glu Ser Phe Glu Gly Gln Met Thr Glu Asp Asn Ile
195 200 205

Glu Val Gly Ile Cys Asn Glu Ala Gly Phe Arg Arg Leu Thr Pro Thr 210 215 220

Glu Val Lys Asp Tyr Leu Ala Ala Ile Ala 225 230